✦ LIBER ✦

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

✍ Scribed by Serge D Steinfeld, Laure Tant, Gerd R Burmester…

Book ID: 120707574
Publisher: BioMed Central
Year: 2006
Tongue: English
Weight: 597 KB
Volume: 8
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar2018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab treatment in patients with pri

Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study

✍ J. Pijpe; G. W. van Imhoff; F. K. L. Spijkervet; J. L. N. Roodenburg; G. J. Wolb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 2 views

Efficacy and safety of belimumab in prim

Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study

✍ Mariette, X.; Seror, R.; Quartuccio, L.; Baron, G.; Salvin, S.; Fabris, M.; Desm 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 968 KB

Phase I/II Study of an Anti-CD30 Monoclo

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

✍ Ansell, S. M.; Horwitz, S. M.; Engert, A.; Khan, K. D.; Lin, T.; Strair, R.; Kel 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 123 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB